role of hypomethylating agents in the novel agent era
Published 4 years ago • 33 plays • Length 1:02Download video MP4
Download video MP3
Similar videos
-
1:09
the changing role of allosct in dlbcl in the era of novel agents
-
1:14
promising novel agents in aml: menin inhibitors
-
3:08
hypomethylating agents in aml
-
1:54
fostamatinib and efgartigimod: novel agents in the treatment of itp
-
3:08
welcome to the video journal of hematology & hematological oncology 🎥🩸
-
2:29
epitope editing enables the use of novel immunotherapies for aml
-
3:48
trials of interest in newly diagnosed myeloma presented at ims 2024
-
1:06:04
itp: novel treatments
-
5:54
addressing the risk of cancer after aav vector dosing in patients with hemophilia
-
4:36
haemonetics
-
3:51
significance of oral hypomethylating agents
-
14:44
the role of allosct in patients with hl who relapse after autosct and the impact of novel agents
-
5:08
combining hypomethylating agents in aml
-
2:12
novel agents of interest for the treatment of bpdcn
-
1:12
hypomethylating agents for low risk mds
-
1:39
the mechanism of action of navtemadlin and its role in mf
-
7:28
mbg453 with hypomethylating agents in aml and high-risk mds
-
1:12
the reduced prognostic impact of the cll-ipi in the new era of targeted agents
-
1:17
novel treatment approaches being explored in amyloidosis: immunotherapeutic agents & venetoclax
-
0:42
the importance of genomic characterization in t-all
-
2:33
novel immunotherapies in aml and insights into the future of the treatment landscape